Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,816,192
  • Shares Outstanding, K 186,851
  • Annual Sales, $ 4,110 K
  • Annual Income, $ -119,360 K
  • 60-Month Beta 1.08
  • Price/Sales 629.03
  • Price/Cash Flow N/A
  • Price/Book 4.70
Trade INO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.26
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.62 +22.39%
on 12/29/20
10.68 -1.22%
on 01/26/21
+0.29 (+2.83%)
since 12/24/20
3-Month
8.26 +27.72%
on 11/09/20
13.94 -24.32%
on 12/04/20
+0.10 (+0.96%)
since 10/26/20
52-Week
3.14 +235.99%
on 02/07/20
33.79 -68.78%
on 06/26/20
+6.31 (+148.82%)
since 01/24/20

Most Recent Stories

More News
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases,...

INO : 10.55 (+8.54%)
INOVIO Announces Pricing of Public Offering of Common Stock

, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases,...

INO : 10.55 (+8.54%)
INOVIO Announces Proposed Public Offering of Common Stock

, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases,...

INO : 10.55 (+8.54%)
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated...

INO : 10.55 (+8.54%)
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

and SUZHOU, , /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer,...

INO : 10.55 (+8.54%)
February 2021 Options Now Available For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available today, for the February 2021 expiration.

INO : 10.55 (+8.54%)
Zika Virus Vaccines Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report titled Zika Virus Vaccines offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product usage and...

CERS : 6.95 (-4.53%)
GSK : 39.21 (+0.75%)
IMV.TO : 4.50 (-1.10%)
INO : 10.55 (+8.54%)
XON : 4.65 (-4.12%)
NLNK : 0.8900 (-12.75%)
TKPYY : 16.5900 (-0.90%)
Company News for Dec 28, 2020

Companies In The News Are: BUD, APO, INO, GOOGL, INTC, CLDR

INTC : 55.14 (-0.54%)
BUD : 65.07 (+0.57%)
APO : 49.06 (+6.93%)
GOOGL : 1,907.26 (+0.69%)
INO : 10.55 (+8.54%)
CLDR : 14.42 (+3.89%)
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

MRNA : 152.25 (+3.57%)
NVAX : 127.31 (-3.16%)
TBIO : 23.09 (-6.25%)
INO : 10.55 (+8.54%)
BNTX : 106.45 (-3.76%)
Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, INO, ODT, COCP, and VUZI.

COCP : 1.95 (-3.47%)
INO : 10.55 (+8.54%)
ODT : 21.95 (+1.76%)
GEVO : 12.69 (-4.15%)
VUZI : 14.76 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 10.88
2nd Resistance Point 10.33
1st Resistance Point 10.02
Last Price 10.57
1st Support Level 9.17
2nd Support Level 8.62
3rd Support Level 8.32

See More

52-Week High 33.79
Fibonacci 61.8% 22.08
Fibonacci 50% 18.47
Fibonacci 38.2% 14.85
Last Price 10.57
52-Week Low 3.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar